Skip to content

Quality of Life Assessment in Patients Who Are Under Surveillance for IPMN

Intraduktaalisen Papillaarisen Musinoosisen Neoplasian Vuoksi Seurannassa Olevien Potilaiden elämänlaatu

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03131076
Enrollment
300
Registered
2017-04-27
Start date
2017-05-01
Completion date
2019-12-31
Last updated
2017-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IPMN, Quality of Life

Brief summary

Over 500 patients were participating in the IPMN follow up between september 2014 and august 2016 at the Helsinki University Hospital. In this study we are going to determine the effects of the IPMN surveillance on the quality of life and anxiety levels of the patients.

Detailed description

Intraductal papillary mucinous neoplasm (IPMN) is a cystic neoplasm of the pancreas. The incidence of the tumors has increased during the last years. Some of the IPMN-tumors develop over time increasing dysplasia and at the end IPMN associated carcinoma. All IPMN-patients are kept under surveillance because of the cancer risk. This follow up can last decades and includes MRI and blood samples every 6 to 12 months. This is very expensive and the effects on the patients quality of life have not been studied before to our knowledge. This study determines the effects of the surveillance on the patients quality of life and anxiety levels. The study will be conducted by 15D- quality of life -questionnaire and state-trait anxiety inventory (STAI) -questionaire. Both will be send to the patients before a IPMN follow up MRI and 3 months later. It is anticipated that the anxiety and the effect on the quality of life would be the highest right before the MRI and would normalize a few months after the MRI.

Interventions

DIAGNOSTIC_TESTIPMN follow up

Follow up with MRI and laboratory blood tests

Sponsors

Helsinki University Central Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* all patients under IPMN surveillance

Exclusion criteria

* no

Design outcomes

Primary

MeasureTime frameDescription
Change in the quality of life and anxietyBefore and 3 months after IPMN follow up MRI15D quality of life and STAI -questionnaire

Contacts

Primary ContactHeini Nieminen
heini.nieminen@hus.fi0035894711
Backup ContactHanna Seppänen
hanna.seppanen@hus.fi0035894711

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026